Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica-Reference-Cited by-同舟云学术

Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica

Published:2021-12-21 Issue: Volume: Page:135245852110497
ISSN:1352-4585
Container-title:Multiple Sclerosis Journal
language:en
Short-container-title:Mult Scler

Author:

Januel Edouard¹,De Seze Jérôme²,Vermersch Patrick³,Maillart Elisabeth¹^ORCID,Bourre Bertrand⁴,Pique Julie⁵,Moisset Xavier⁶^ORCID,Bensa Caroline⁷,Maarouf Adil⁸^ORCID,Pelletier Jean⁸,Vukusic Sandra⁵^ORCID,Audoin Bertrand⁸^ORCID,Louapre Céline¹

Affiliation:

1. Assistance Publique des Hôpitaux de Paris, Hôpital de la Pitié Salpêtrière, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique, Neuroscience Clinical Investigation Center, Paris Brain Institute, Sorbonne Université, Paris, France

2. Service de Neurologie and CIC INSERM 1434, CHU de Strasbourg, Strasbourg, France

3. Univ. Lille, Inserm UMR-S1172, CHU Lille, FHU Precise, Lille, France

4. Centre Hospitalier Universitaire Rouen Normandie, Hôpital Charles-Nicolle, Service de Neurologie, Rouen, France

5. Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Lyon, France

6. Department of Neurology, Neuro-Dol, CHU Clermont-Ferrand, Université Clermont Auvergne, INSERM U1107, Clermont-Ferrand, France

7. Department of Neurology, Hôpital Fondation Adolphe de Rothschild, Paris, France

8. APHM, Hôpital de la Timone, Pôle de Neurosciences Cliniques, Service de Neurologie, Aix Marseille Univ, Marseille, France/Aix-Marseille University, CRMBM UMR 7339, CNRS, Marseille, France

Abstract

Introduction: Recent studies suggested that anti-CD20 and fingolimod may be associated with lower anti-spike protein-based immunoglobulin-G response following COVID-19 vaccination. We evaluated if COVID-19 occurred despite vaccination among patients with multiple sclerosis (MS) and neuromyelitis optica (NMO), using the COVISEP registry. Case series: We report 18 cases of COVID-19 after two doses of BNT162b2-vaccination, 13 of which treated with anti-CD20 and four with fingolimod. COVID-19 severity was mild. Discussion: These results reinforce the recommendation for a third COVID-19 vaccine dose among anti-CD20 treated patients and stress the need for a prospective clinical and biological study on COVID-19 vaccine efficacy among MS and NMO patients.

Publisher

SAGE Publications

Subject

Neurology (clinical),Neurology

Link

http://journals.sagepub.com/doi/pdf/10.1177/13524585211049737

Reference9 articles.

1. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

2. DMTs and Covid‐19 severity in MS: a pooled analysis from Italy and France

3. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis

4. GERS: Groupement pour l’Élaboration et la Réalisation de Statistiques. Disponible sur, https://www.sas.gie-gers.fr/qualite/cahier_charges.php3?id_contenu=54 [accessed 2 August 2021).

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real World Use of Tixagevimab/Cilgavimab Pre-Exposure Prophylaxis of COVID-19 in Immunocompromised Individuals: Data from the OCTOPUS Study;Vaccines;2024-07-17

2. Association Between Anti-CD20 Therapies and COVID-19 Severity Among Patients With Relapsing-Remitting and Progressive Multiple Sclerosis;JAMA Network Open;2023-06-23

3. Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1-phosphate receptor modulators;Multiple Sclerosis and Related Disorders;2023-02

4. Safety, immunogenicity, efficacy, and acceptability of COVID-19 vaccination in people with multiple sclerosis: a narrative review;Neural Regeneration Research;2023

5. Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes;Multiple Sclerosis and Related Disorders;2022-11